Autoimmune hemolytic anemia

From Citizendium
Revision as of 12:55, 8 September 2020 by imported>Pat Palmer (adding subpages)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
This article is a stub and thus not approved.
Main Article
Discussion
Definition [?]
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and subject to a disclaimer.

In hematology, Autoimmune hemolytic anemia (AIHA) is an "acquired hemolytic anemia due to the presence of autoantibodies which agglutinate or lyse the patient's own red blood cells."[1]

Classification

Diagnosis

Treatment

As of 2010, no randomized controlled trials were available.[6] Subsequent studies are below.

Rituximab, a monoclonal antibody, was found to be safe by a systematic review of 21 studies, although only one was a randomized controlled trials.[7]

References